US Stem Cell Inc
U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which compl… Read more
US Stem Cell Inc (USRM) - Total Liabilities
Latest total liabilities as of March 2023: $14.81 Million USD
Based on the latest financial reports, US Stem Cell Inc (USRM) has total liabilities worth $14.81 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
US Stem Cell Inc - Total Liabilities Trend (2002–2022)
This chart illustrates how US Stem Cell Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
US Stem Cell Inc Competitors by Total Liabilities
The table below lists competitors of US Stem Cell Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DAIWA COMPUTER
BE:M2V
|
Germany | €1.02 Billion |
|
XMax Inc.
NASDAQ:XWIN
|
USA | $4.70 Million |
|
Aquarius Surgical Technologies Inc
PINK:AQQRF
|
USA | $8.09 Million |
|
EDEL (EDL.SG)
STU:EDL
|
Germany | €142.63 Million |
|
YAMAHA CORP - Dusseldorf Stock Exchang
DU:YHA
|
Germany | €155.03 Billion |
|
ALLOT COMMUN (AG6.SG)
STU:AG6
|
Germany | €85.75 Million |
Liability Composition Analysis (2002–2022)
This chart breaks down US Stem Cell Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 217.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how US Stem Cell Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for US Stem Cell Inc (2002–2022)
The table below shows the annual total liabilities of US Stem Cell Inc from 2002 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $14.81 Million | +15.57% |
| 2021-12-31 | $12.82 Million | +9.86% |
| 2020-12-31 | $11.67 Million | +21.93% |
| 2019-12-31 | $9.57 Million | +10.00% |
| 2018-12-31 | $8.70 Million | +0.01% |
| 2017-12-31 | $8.70 Million | +2.98% |
| 2016-12-31 | $8.45 Million | +6.24% |
| 2015-12-31 | $7.95 Million | -28.37% |
| 2014-12-31 | $11.10 Million | -19.77% |
| 2013-12-31 | $13.83 Million | -6.27% |
| 2012-12-31 | $14.76 Million | +20.19% |
| 2011-12-31 | $12.28 Million | -0.37% |
| 2010-12-31 | $12.32 Million | -19.33% |
| 2009-12-31 | $15.28 Million | -5.05% |
| 2008-12-31 | $16.09 Million | -4.39% |
| 2007-12-31 | $16.83 Million | +665.90% |
| 2006-12-31 | $2.20 Million | +71.31% |
| 2005-12-31 | $1.28 Million | -50.40% |
| 2004-12-31 | $2.59 Million | +75.32% |
| 2003-12-31 | $1.48 Million | -15.81% |
| 2002-12-31 | $1.75 Million | -- |